IPO Trending
SENORESEQ / NSE, BSEListed
Senores Pharmaceuticals

Senores Pharmaceuticals Limited, incorporated on December 26, 2017, is an Ahmedabad-based pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded generic medicines for both domestic and global markets. Its diversified product portfolio spans key therapeutic areas, including gastrointestinal, cardiovascular, respiratory, pain management, and anti-infective segments. Driven by strong R&D capabilities, the company emphasizes innovation, cost-effective product development, and strict regulatory compliance. Senores operates through a robust distribution network supported by subsidiaries such as Ratnatris Pharmaceuticals Private Limited and Havix Group, Inc. (Aavis Pharmaceuticals). It serves customers across major international markets, including the US, Europe, and other emerging regions.

₹372 - ₹39197.25x sub
Listed Price₹600.00
Listing Gain+53.45%

Subscription Status

97.25xTotal Demand
Updated 20 Oct 2026, 01:30 AM
Subscription PendingExchange subscription breakup is not available yet.

Category-wise demand has not been published yet. Check back after the exchange updates the live subscription feed.

Open Date20 Dec 2024
Close Date24 Dec 2024
Listing Date30 Dec 2024
Bidding status cross-verified with live IPO subscription numbers ↗BSE & NSE Bidding Portal Feed

About Senores Pharmaceuticals IPO Subscription Demand

Live subscription status and bidding analysis for Senores Pharmaceuticals (SENORES) IPO. The issue is subscribed 97.25x overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII/HNI), and Retail Individual Investors (RII). Check real-time grey market demand on our GMP Tracker or review full issue details, lot size, and price band on the IPO Details Page.

Frequently Asked Questions